<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452907</url>
  </required_header>
  <id_info>
    <org_study_id>ARTEN_L_00848</org_study_id>
    <nct_id>NCT00452907</nct_id>
  </id_info>
  <brief_title>ACT MALI: Treatment of Malaria Based on Combination Therapies</brief_title>
  <official_title>Assessment of the Public Health Benefit of Artemisinine Based Combination Therapies for Uncomplicated Malaria Treatment in Mali</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Test the hypothesis that repeated administration of Artesunate/Amiodaquine,
      Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of
      consecutive episodes of uncomplicated malaria reduces the incidence of uncomplicated
      falciparum malaria and malaria attributable anemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and parasitological cure rate</measure>
    <time_frame>at day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical and biological tolerability</measure>
    <time_frame>During the study period</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">780</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arsucam® (AS 50mg/Aq153mg),oad, per os, 3 days of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arsumax (AS 50mg) + Sulfadoxine-Pyrimethamine (SP=SDX 500mg/PYR 25mg), oad, per os</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coartem (arthemether 20mg+ lumefantrine 120 mg), bid, per os. Duration of treatment: 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate</intervention_name>
    <description>oad, per os, 3 days of treatment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate + Sulfadoxine-Pyrimethamine</intervention_name>
    <description>oad, per os</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arthemether + lumefantrine</intervention_name>
    <description>bid, per os. Duration of treatment: 3 days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight &gt; 5kg

          -  Residence in the investigator site area for the duration of the trial

          -  Axillary temperature ≥ 37,5°C at Day 0

          -  Confirmed Plasmodium falciparum infection,with parasitemia range from 2000 to 200000
             asexual parasites /µl of blood

        Exclusion Criteria:

          -  Danger signs or signs of severe malaria

          -  Other severe illnesses

          -  Allergy to one of the drugs

          -  Pregnant women

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Lameyre</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bougoula</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mali</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2007</study_first_posted>
  <last_update_submitted>February 16, 2010</last_update_submitted>
  <last_update_submitted_qc>February 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

